{"type":"trials","record":{"id":42118,"source_id":"clinicaltrials-gov","external_id":"NCT05135195","title":"A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training","brief_summary":"In this study, the study team utilize virtual reality (VR) to simulate visual impairments of different types and severity in healthy subjects. The platform implements three of the most widespread forms of visual impairment in the United States (US): age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, each with three levels of severity, (mild, moderate, and severe). At present, glaucoma is further developed toward a multidimensional visual impairment simulation. The platform is utilized: i) to provide a safe, controllable, and repeatable set of environments for development and preliminary testing of electronic travel aids (ETAs) in a variety of conditions (i.e., using the ETA to navigate in the immersed environment); and ii) to equip blind and low vision (BVI) professionals, inclusive of orientation and mobility (O\\&M) instructors, with a controlled, tunable training platform for skill/capacity building, assessment, and refinement of O\\&M techniques, as well as visually impaired trainees with a safe and immersive environment to improve their O\\&M skills and learn novel techniques. Two sets of hypothesis-driven experiments are proposed to assess the feasibility of the platform with respect to these two objectives.","overall_status":"Completed","phases":[],"study_type":"INTERVENTIONAL","sponsor":"NYU Langone Health","enrollment":98,"countries":["United States"],"start_date":"2021-10-24","completion_date":"2022-10-20","last_update_date":"2023-07-03","source_url":"https://clinicaltrials.gov/study/NCT05135195","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years to 80 Years","comparator":null,"organization":"NYU Langone Health","interventions":["In-House Developed VR Platform - AMD, DR, Glaucoma","In-House Developed VR Platform - Glaucoma"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Average time to complete the trial — 1 Day of Intervention","Average number of obstacle collisions during the trial — 1 Day of Intervention","Average travel time — 1 Day of Intervention","Average distance traveled by the participant — 1 Day of Intervention","Preferred walking speed — 1 Day of Intervention","Orientation — 1 Day of Intervention","Number of instances in which the participant stop for more than 2 seconds — 1 Day of Intervention","Total time spent during stops of more than 2 seconds — 1 Day of Intervention","Average time it takes to understand how to interact with the system and run the simulation of the bus ride — 1 Day of I…"],"design_description":"NON RANDOMIZED · PARALLEL · SCREENING · NONE","source_has_results":false},"controlled_terms":["Visual Impairment","Age-Related Macular Degeneration","Diabetic Retinopathy","Glaucoma","In-House Developed VR Platform - AMD, DR, Glaucoma","In-House Developed VR Platform - Glaucoma"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05135195","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-10-24 to 2022-10-20","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.923Z","intervention":["In-House Developed VR Platform - AMD, DR, Glaucoma","In-House Developed VR Platform - Glaucoma"],"participants":98,"study_design":"NON RANDOMIZED · PARALLEL · SCREENING · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Average time to complete the trial — 1 Day of Intervention","Average number of obstacle collisions during the trial — 1 Day of Intervention","Average travel time — 1 Day of Intervention","Average distance traveled by the participant — 1 Day of Intervention","Preferred walking speed — 1 Day of Intervention","Orientation — 1 Day of Intervention","Number of instances in which the participant stop for more than 2 seconds — 1 Day of Intervention","Total time spent during stops of more than 2 seconds — 1 Day of Intervention","Average time it takes to understand how to interact with the system and run the simulation of the bus ride — 1 Day of I…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42118","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}